Strict US written description and enablement requirement applied to ADCs and platform inventions (Seagen v Daiichi Sankyo)

The strict US patentability requirements of written description and enablement do not just apply to antibodies, but may be the downfall of any broadly claimed biologic or biotech platform invention. The recent decision of the US Court of Appeals for the Federal Circuit in Seagen v. Daiichi Sankyo overruled the jury decision in the District Court to find an ADC linker platform patent invalid